Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany

被引：0
|
作者：
Heinze, A. [1 ]
Totev, T. [2 ]
Krasenbaum, L. [3 ]
Terasawa, E. [4 ]
Akcicek, H. [5 ]
Hipp, J. [5 ]
Sun, R. [2 ]
Yim, E. [2 ]
Driessen, M. [5 ]
机构：
[1] Pain Clin Kiel, Migraine & Headache Ctr, Kiel, Germany
[2] Anal Grp Inc, Boston, MA USA
[3] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[4] Anal Grp Inc, New York, NY USA
[5] Teva Pharmaceut, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-075
引用
收藏
页码：419 / 419
页数：1
相关论文
共 50 条
  • [31] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    HEADACHE, 2021, 61 : 71 - 72
  • [32] First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry
    Peikert, Andreas
    Koerwer, Monika
    Tozzi, Viola
    Dikow, Heidi
    Rossnagel, Fabian
    Schnabel, Silvio
    Braune, Stefan
    Bergmann, Arnfin
    NEUROLOGY, 2020, 94 (15)
  • [33] One year outcome of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Nasergivehchi, Somayeh
    Cheng, Fan
    Hussain, Mariam
    Khalil, Modar
    Ahmed, Fayyaz
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 130 - 130
  • [34] Two year outcome of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Khan, Rafiullah
    Nasergivehchi, Somayeh
    Khalil, Modar
    Delroasario, Helen
    Ahmed, Fayyaz
    CEPHALALGIA, 2023, 43 (1supp) : 269 - 270
  • [35] PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
    Ashina, Messoud
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Cohen, Joshua M.
    Konings, Martijn
    Tassorelli, Cristina
    Lyras, Leonidas
    Mitsikostas, Dimos-Dimitrios
    PAIN MANAGEMENT, 2021, 11 (06) : 647 - 654
  • [36] Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
    McAllister, Peter
    Lamerato, Lois
    Krasenbaum, Lynda J.
    Cohen, Joshua M.
    Tangirala, Krishna
    Thompson, Stephen
    Driessen, Maurice
    Casciano, Julian
    Dotiwala, Zenobia
    Mauskop, Alexander
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [37] Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
    Peter McAllister
    Lois Lamerato
    Lynda J. Krasenbaum
    Joshua M. Cohen
    Krishna Tangirala
    Stephen Thompson
    Maurice Driessen
    Julian Casciano
    Zenobia Dotiwala
    Alexander Mauskop
    The Journal of Headache and Pain, 2021, 22
  • [38] Reductions in Migraine Frequency with Fremanezumab Treatment by Baseline Migraine Frequency Category in Patients with Chronic and Episodic Migraine
    Nahas, Stephanie J.
    Ning, Xiaoping
    Cohen, Joshua M.
    Barash, Steve
    Campos, Verena Ramirez
    Carr, Karen
    Silberstein, Stephen D.
    ANNALS OF NEUROLOGY, 2021, 90 : S133 - S134
  • [39] Real-world data on erenumab interruption in migraine patients in Germany: the SPECTRE study
    Gaul, Charly
    Goebel, Hartmut
    Koch, Mirja
    Weiss, Cordula
    CEPHALALGIA, 2023, 43 (1supp) : 232 - 233
  • [40] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway
    Waliszewska-Prosol, Marta
    Martelletti, Paolo
    DENTAL AND MEDICAL PROBLEMS, 2024, 61 (01) : 9 - 11
12345